3 completed, 2 recruiting. 2 Phase 1, 2 Phase 2, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow InnoPharmax Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer D07001-Softgel Capsules, Placebo, Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | InnoPharmax Inc. | 240 | 2026-06-09 | 2026-07-30 |
| Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX - Biliary Tract Cancer | Phase 2 / Phase 3 | Recruiting | InnoPharmax Inc. | 180 | 2022-03-29 | 2025-04-30 |
| Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase D07001-softgel capsules - Gastrointestinal Cancer, Biliary Tract Cancer | Phase 1 / Phase 2 | Completed | InnoPharmax Inc. | 19 | 2018-08-06 | 2023-11-24 |
| Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas Gemcitabine HCl Oral Formulation - Advanced Solid Malignancies, Malignant Lymphomas | Phase 1 | Completed | InnoPharmax Inc. | 37 | 2013-04-01 | 2019-07-08 |
| An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors Gemcitabine HCl Oral Formulation - Malignant Tumors | Early Phase 1 | Completed | InnoPharmax Inc. | 11 | 2012-08-01 | 2016-09-02 |
Biliary Tract Neoplasms (3) · Cholangiocarcinoma (1) · Gastrointestinal Neoplasms (1) · Lymphoma (1) · Neoplasms (1)
Capecitabine (2) · Control Groups (1) · titanium silicide (1)
Taiwan (5) · United States (2)
Chia-Chi Lin, MD (2) · Criss Cheng (1) · Li-Tzong Chen, Ph. D (1) · Li-Tzong Chen, Ph.D (1) · Nashat Y. Gabrail, MD (1) · Sharad Ghamande, MD (1) · Wu-Chou Su, MD (1) · Yee Chao, MD (1)